Clinical trial · Interventional
Prevention of Cancer-associated Malnutrition Through Oral Nutritional Supplements
Prevention of Malnutrition Through Oral Nutritional Supplements in Cancer Patients Receiving Palliative Therapy
NCT02312674CI-TRIAL-00016297unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of the randomized controlled study is to determine effects of an adjusted amount of oral nutritional supplements on the quality of life, the nutritional status, side effects, and response to therapy, in patients with pancreatic and hepatocellular carcinoma receiving palliative therapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Oral nutritional supplement | Dietary Supplement | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Intervention
- description
- Patient group which takes daily an adjusted amount of oral nutritional supplements through an intervention period of three months
- interventionNames
- Dietary Supplement: Oral nutritional supplement
- type
- NO_INTERVENTION
- label
- Control
- description
- Patients group which takes no oral nutritional supplements
Primary outcomes (2)
- measure
- Change in health-related quality of life
- timeFrame
- Every four weeks for a period of three months and after six months
- description
- Health-related quality of life is assessed by using the standardized questionnaire "Short Form-36 Health Survey" (SF36).
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * assured diagnosis of pancreatic cancer/hepatocellular carcinoma, not treatable with curative intent * palliative systemic therapy of pancreatic cancer respectively palliative therapy of hepatocellular carcinoma with Sorafenib or TACE (transarterial chemoembolization) * written informed consent prior to inclusion Exclusion Criteria: * prefinal phase with an estimated life expectancy of less than three months * nutritional support through tube feeding or a central venous catheter * serious malassimilation (assessed by anamnesis) * Eastern Cooperative Oncology Group (ECOG) Performance Status ≥ 2 * hepatic encephalopathy ≥ degree 2
References
Publications (0)
Data not yet available
No reference posted for this study.